TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19833566
Drug: Leukocytapheresis (LAP)
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytapheresis (LAP) plus steroids
Study: 19032173
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g piperacillin
Study: 19032173
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g piperacillin
Study: 15927814
Drug: FX cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX cream (0.02% farnesol and 5% xylitol)
Study: 12831141
Drug: Latanoprost (topically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost (topically applied once daily in the evening for 12 weeks)
Study: 12831141
Drug: Brimonidine (applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine (applied twice daily for 6 weeks, with 16 patients continuing for 12 weeks)
Study: 8796775
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (50 micrograms)
Study: 8382104
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day for an average of 8 days)
Study: 22156181
Drug: Additional written
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional written information about orthodontic treatment
Study: 20112575
Drug: Cheezheng Qingpeng
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheezheng Qingpeng ointment
Study: 16936533
Drug: Low-dose fixed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fixed combination of perindopril 2 mg and indapamide 0.625 mg
Study: 16936533
Drug: Standard guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard guidelines based therapy for glucose control
Study: 11783459
Drug: Herbal anticellulite
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal anticellulite pill plus supplements of conjugated linoleic acid
Study: 11783459
Drug: Herbal anticellulite
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal anticellulite pill
Study: 1651610
Drug: Serotype 1
Normalized name: Aspergillus fumigatus serotype 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype 1 reassortant vaccine (10^4 p.f.u.)
Study: 1651610
Drug: Serotype 2
Normalized name: Pneumococcal polysaccharide serotype 23F
DrugBank: Streptococcus pneumoniae type 23f capsular polysaccharide antigen (DB10340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype 2 reassortant vaccine (10^4 p.f.u.)
Study: 1651610
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serotype 1 and serotype 2 vaccines (0.5 x 10^4 p.f.u. of each)
Study: 1651610
Drug: Trivalent combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent combination (0.33 x 10^4 p.f.u. of each strain)
Study: 1651610
Drug: Various vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various vaccines and combinations
Study: 6321376
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ORG 2766
Study: 25132516
Drug: PEGASUS psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGASUS psychoeducational programme (n = 24), administered in six weekly group sessions.
Study: 24001010
Drug: Spontaneous inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous inhibitor clearance in patients not undergoing ITI
Study: 24001010
Drug: Inhibitor titre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor titre and gene mutation
Study: 24001010
Drug: Cumulative incidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative incidence of inhibitors
Study: 24001010
Drug: Permanent inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent inhibitors
Study: 24001010
Drug: Transient inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transient inhibitors
Study: 19922681
Drug: Combination reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination reverse transcriptase inhibitors
Study: 17257428
Drug: Urodilatin (URO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodilatin (URO) infusion for 90 minutes
Study: 11869325
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BT) injection (80 units in five cases, 60 units in two cases) into four quadrants of lower esophageal sphincter (LES)
Study: 11869325
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (BT and pneumatic dilatation)
Study: 9272237
Drug: Levosimendan 1
Normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 1 mg intravenously
Study: 9272237
Drug: Ethanol 0.8
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.8 g/kg alone
Study: 1169822
Drug: Intravenous dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextran 40
Study: 1598096
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin
Study: 24052987
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg/day for at least 6 months)
Study: 25665208
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of 5 mg x kg(‐1) of body weight of caffeine and 200 mg of Panax ginseng
Study: 19909587
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (letrozole, 5 mg/day) + rFSH (450 IU/day)
Study: 15564955
Drug: Haloperidol 0.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.5-4 mg
Study: 18420852
Drug: Haloperidol 1
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1 mg
Study: 10673291
Drug: Quadruple antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple antibiotic therapy for one day
Study: 10673291
Drug: Quadruple antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple antibiotic therapy for two days
Study: 9300248
Drug: High 2-h
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High 2-h plasma NEFA and low 2-h plasma insulin concentrations in IGT subjects
Study: 9300248
Drug: 2-h plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-h plasma insulin concentration in subjects with IGT who deteriorated
Study: 8449086
Drug: Heparin 4
Normalized name: heparin 40000 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 4 U/ml
Study: 3518910
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 200 mg intramuscularly weekly for 4 weeks
Study: 23601186
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (Control)
Study: 24635110
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with RT and concurrent chemotherapy
Study: 22017192
Drug: Duloxetine 60/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60/120 mg/day
Study: 20546509
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/day (for previously placebo-treated patients)
Study: 15809017
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g oral arginine
Study: 15809017
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g oral arginine
Study: 15809017
Drug: 13 g
Normalized name: UREA 13 g TOPICAL TABLET [CLEAN-UP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 g oral arginine
Study: 11977435
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy for insomnia
Study: 10084473
Drug: Salmeterol, 42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 42 microg, twice daily
Study: 2257960
Drug: Serratia peptidase
Normalized name: Serratia marcescens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratia peptidase (two tablets three times a day for 7-8 days)
Study: 2257960
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets three times a day for 7-8 days)
Study: 366145
Drug: Levamisole treatment
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole treatment
Study: 30819262
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (38 µg or 1500 IU daily) with iron-fortified breakfast cereal
Study: 28535235
Drug: Cephalexin plus
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin plus trimethoprim‐sulfamethoxazole (500 mg 4 times daily, plus 320 mg/1600 mg twice daily for 7 days)
Study: 28535235
Drug: Cephalexin alone
Normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin alone (500 mg 4 times daily for 7 days)
Study: 25812064
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant extract (300 mg·day‐1 CurraNZ; containing 105 mg anthocyanin)
Study: 23844168
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral levodopa
Study: 18604074
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg/kg mixed in paracetamol syrup
Study: 15464773
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg/day, n=20)
Study: 15464773
Drug: CPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA plus EE2 (CPA 25 mg/day on days 5-14 plus EE2 20 microg/day on days 5-25, n=20)
Study: 9721345
Drug: Fibrinolysis (FB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolysis (FB) treatment in AMI patients
Study: 9721345
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in AMI patients (without FB)
Study: 8040676
Drug: Salvage therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapies (chemotherapy, hormonal therapy, combination of cytotoxic and hormonal therapies)
Study: 8040676
Drug: Second-line hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-line hormonal therapy
Study: 8040676
Drug: First salvage
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First salvage therapy
Study: 4161578
Drug: Isoniazid (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (average 6.9 mg/kg) plus thioacetazone (average 3.4 mg/kg), daily in one dose
Study: 4161578
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of isoniazid (average 4.5 mg/kg body-weight) plus sodium PAS (average 0.22 g/kg), daily in two divided doses
Study: 4161578
Drug: 2-phase regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-phase regimen of isoniazid (average 5.5 mg/kg) plus sodium PAS (average 0.17 g/kg), daily in one dose for 6 months, followed by isoniazid alone (average 6.8 mg/kg), daily in one dose for the second 6 months
Study: 28074392
Drug: Cerebrolysin (CBL)
Normalized name: OH-Cbl
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (CBL) administered intramuscularly as a single daily dose of 0.1 cc/kg for 10 days, then continued weekly for 4 months.
Study: 28074392
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard rehabilitation therapy without CBL.
Study: 25971261
Drug: Ribavirin (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (dosing simulations)
Study: 24011102
Drug: Teens and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teens and Toddlers intervention (18-20 weekly sessions in pre-school nurseries)
Study: 12792150
Drug: Mesterolone 100
Normalized name: mesterolone
DrugBank: Mesterolone (DB13587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone 100 mg p.o. daily
Study: 12792150
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 160 mg p.o. daily
Study: 12792150
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 250 mg i.m. every 21 days
Study: 12792150
Drug: Crystalline testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalline testosterone 1,200 mg subcutaneous implantation
Study: 10383596
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg twice daily for 8 weeks
Study: 8707338
Drug: CAMPATH‐1H (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMPATH‐1H (humanized antibody against the CD52 antigen)
Study: 31340801
Drug: Intravesical gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical gemcitabine monotherapy
Study: 24938580
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily for 8 weeks
Study: 20845204
Drug: Embodied Conversational
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embodied Conversational Agents (ECA) for automated health communication interventions
Study: 11411817
Drug: Paroxetine (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-50 mg/day)
Study: 18095197
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg gabapentin
Study: 24190578
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg gabapentin
Study: 20565316
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of topical amphotericin B (0.5 mg/mL) eye drops with subconjunctival injection of fluconazole (2 mg/mL)
Study: 20565316
Drug: Topical amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical amphotericin B (0.5 mg/mL) eye drops alone
Study: 19029209
Drug: Biological assignment
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological assignment trials
Study: 10696421
Drug: Self-supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-supervised treatment (SS)
Study: 10696421
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Treatment (DOT) at district and provincial hospitals
Study: 10696421
Drug: Self-supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-supervised treatment (SS) at district and provincial hospitals
Study: 10696421
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Treatment (DOT) at referral centres
Study: 10696421
Drug: Self-supervised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-supervised treatment (SS) at referral centres
Study: 8572663
Drug: Deprenyl 10
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 10 mg/day (open label)
Study: 9159313
Drug: Povidone-iodine ointment
Normalized name: Povidone-Iodine Ointment
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine ointment
Study: 6195241
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no povidone-iodine ointment)
Study: 29764260
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical fatigue and mental stress
Study: 27577509
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 80 kVp tube voltage, 270 mg iodine (I)/mL contrast agent (Visipaque, GE Healthcare)
Study: 27577509
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 100 kVp tube voltage, 370 mg I/mL contrast agent (Iopamiro, Bracco)
Study: 24574444
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg before surgery, followed by 600 mg on day 1, 900 mg on day 2, and 1200 mg on days 3-5)
Study: 17996818
Drug: Automated, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated, daily symptom and self-reported weight monitoring intervention
Study: 177803
Drug: 0.15 g
Normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 g phenformin
Study: 177803
Drug: 2.55 g
Normalized name: citrate phosphate dextros soln 299 mg-2.63 gram-222 mg-2.55 gram/100 mL MISCELL SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.55 g metformin
Study: 177803
Drug: 0.30 g
Normalized name: Titanium Dioxide 0.30 g in 3.5 g TOPICAL POWDER [3CE TRIPLE SHADOW LEMME SEE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 g buformin
Study: 177803
Drug: biguanide treatment
Normalized name: biguanide
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biguanide treatment
Study: 23868188
Drug: Tivozanib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.5 mg with weekly paclitaxel 90 mg/m²
Study: 23868188
Drug: Tivozanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib plus weekly paclitaxel
Study: 21619503
Drug: Local infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infusion analgesia (LINFA) with Ropivacain, Ketorolac, and Adrenaline administered through a catheter
Study: 21619503
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered through a catheter
Study: 21619503
Drug: Local infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infusion analgesia (LINFA)
Study: 21641354
Drug: Transendocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial injection of autologous bone marrow mononuclear cells (ABMMNCs)
Study: 15364865
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ABMMNC injection)
Study: 22964967
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg)
Study: 8834129
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 10 mg/day)
Study: 2390281
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (group A - 27 patients)
Study: 7361799
Drug: 5th-grade level
Normalized name: Food Grade Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5th-grade level warfarin drug monograph
Study: 7361799
Drug: 10th-grade level
Normalized name: Food Grade Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10th-grade level warfarin drug monograph
Study: 21060031
Drug: Venlafaxine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (37.5 mg daily for 7 days followed by 75 mg daily for 21 days)
Study: 21060031
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg once per day for 3 days, then 300 mg twice per day for 3 days, then 300 mg three times per day for 22 days)
Study: 15859023
Drug: 7.5% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% NaCl infusion
Study: 2791122
Drug: Gamma-neutron irradiation
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-neutron irradiation using 252Cf, physical dose 2 Gy
Study: 31225839
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention consisting of four one‐on‐one sessions with a nurse interventionist during the patient's first, second, fourth, and sixth week of radiation treatment
Study: 23880908
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg (n=22)
Study: 22910758
Drug: Intensive dose
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dose statin therapy
Study: 19261367
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (verapamil and diltiazem)
Study: 19261367
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (verapamil)
Study: 19261367
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (diltiazem)
Study: 15183850
Drug: 10% solution
Normalized name: Mucomyst 10% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% solution (v/v) of essential oil of Australian lemon myrtle (Backhousia citriodora)